Company

Natera, Inc.

Natera develops cell-free DNA tests for oncology, women's health, and organ health.

About

Founded in 2004 and based in San Carlos, US, Natera develops noninvasive diagnostic tests using cell-free DNA technology. Its products include the Signatera residual disease test and Panorama prenatal test, used in oncology, women's health, and organ health. The company reported USD 1,696.91 mn in revenue and USD -191.32 mn in EBITDA in 2024. In April 2019, it raised USD 250.00 mn in a private placement/follow-on round.

8Funding rounds

12Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in